<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00111878</url>
  </required_header>
  <id_info>
    <org_study_id>MI-CP119</org_study_id>
    <nct_id>NCT00111878</nct_id>
  </id_info>
  <brief_title>Study to Evaluate MEDI-534 in Healthy Adults</brief_title>
  <official_title>Dose-Escalating Study to Evaluate MEDI-534 in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedImmune LLC</source>
  <brief_summary>
    <textblock>
      The primary objective of this study is to describe the safety and tolerability of a single&#xD;
      dose of MEDI-534 when administered to healthy adult volunteers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <completion_date>December 2005</completion_date>
  <study_type>Observational</study_type>
  <study_design_info>
    <observational_model>Defined Population</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment>120</enrollment>
  <condition>Respiratory Syncytial Virus Infections</condition>
  <condition>Parainfluenza Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI-534</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female ages 18 through 40 years (not yet reached their 41st birthday) on the&#xD;
             day of randomization&#xD;
&#xD;
          -  Healthy by medical history and physical examination&#xD;
&#xD;
          -  Available by telephone&#xD;
&#xD;
          -  Signed written informed consent and Health Insurance Portability and Accountability&#xD;
             Act (HIPAA) authorization obtained from the volunteer&#xD;
&#xD;
          -  Sexually active females, unless surgically sterile or at least 1 year post-menopausal,&#xD;
             must have used an effective method of avoiding pregnancy (including oral, implanted,&#xD;
             or transdermal contraceptives, intrauterine device (IUD), female condom, diaphragm&#xD;
             with spermicide, cervical cap, abstinence, use of a condom by the sexual partner or&#xD;
             sterile sexual partner) for at least 30 days prior to dosing of study vaccine, and&#xD;
             must agree to continue using such precautions for at least 30 days after dosing; the&#xD;
             volunteer must also have a negative serum pregnancy test within 7 days prior to dosing&#xD;
             of study vaccine and a negative urine pregnancy test on the day of study vaccine&#xD;
             dosing prior to administration&#xD;
&#xD;
          -  Sexually active males, unless surgically sterile, must use an effective method of&#xD;
             birth control (condom or abstinence) and must agree to continue using such precautions&#xD;
             for at least 30 days after dosing&#xD;
&#xD;
          -  Ability to understand and comply with the requirements of the protocol as judged by&#xD;
             the investigator&#xD;
&#xD;
          -  Ability to complete the follow-up period of 6 months following dosing as required by&#xD;
             the protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute illness on the day of randomization&#xD;
&#xD;
          -  Fever (greater than or equal to 99.5°F oral or greater than or equal to 100.1°F&#xD;
             tympanic) and/or respiratory illness (e.g., cough or sore throat) within 7 days prior&#xD;
             to randomization&#xD;
&#xD;
          -  Any drug therapy (chronic or other) within 7 days prior to randomization (except for&#xD;
             certain medications such as contraceptives, topical [i.e., dermatologic]&#xD;
             corticosteroids, or infrequent use of over-the-counter pain relievers, following&#xD;
             approval from the sponsor) or expected receipt through 28 days after study vaccine&#xD;
             dosing&#xD;
&#xD;
          -  Receipt of immunoglobulin or blood products within 90 days prior to screening or&#xD;
             expected receipt through 28 days after study vaccine dosing&#xD;
&#xD;
          -  Receipt of any investigational drug within 60 days prior to randomization or expected&#xD;
             receipt during the study period (i.e., through 180 days after study vaccine dosing)&#xD;
&#xD;
          -  Receipt of an approved vaccine within 30 days prior to randomization or expected&#xD;
             receipt through 28 days after study vaccine dosing&#xD;
&#xD;
          -  History of immunodeficiency or receipt of immunosuppressive agents, or expected&#xD;
             receipt of an immunosuppressive agent through 28 days after study vaccine dosing&#xD;
&#xD;
          -  Close contact at home or in the workplace with children under 2 years of age&#xD;
&#xD;
          -  Household contact who is immunocompromised; volunteer should also avoid close contact&#xD;
             with immunocompromised individuals for at least 21 days after vaccination&#xD;
&#xD;
          -  History of hypersensitivity to kanamycin or other aminoglycoside antibiotics&#xD;
             (gentamicin, tobramycin, etc.)&#xD;
&#xD;
          -  Previous medical history, or evidence, of an intercurrent or chronic illness that, in&#xD;
             the opinion of the investigator, may compromise the safety of the volunteer&#xD;
&#xD;
          -  Any evidence of end organ dysfunction&#xD;
&#xD;
          -  Current, or history of, clinically significant abnormality on electrocardiogram (ECG)&#xD;
             (screening ECG must be within 30 days prior to randomization)&#xD;
&#xD;
          -  Evidence of active infection with HIV or hepatitis A, B, or C virus, or serologic&#xD;
             evidence of past infection with hepatitis B or C virus&#xD;
&#xD;
          -  At screening (must be within 7 days prior to randomization), any of the following&#xD;
             laboratory tests outside of the laboratory normal range: CBC: hemoglobin (Hgb), WBC&#xD;
             count, platelet count; AST, ALT, BUN, creatinine; or other abnormal laboratory value&#xD;
             in the screening panel that, in the opinion of the principal investigator, may&#xD;
             potentially confound analysis of study results&#xD;
&#xD;
          -  Nursing mother&#xD;
&#xD;
          -  History of alcohol or drug abuse in the past 2 years&#xD;
&#xD;
          -  History of medical diagnosis of asthma, reactive airway disease, or chronic&#xD;
             obstructive pulmonary disease (COPD)&#xD;
&#xD;
          -  History of any smoking in the past 5 years&#xD;
&#xD;
          -  Previous vaccination against Respiratory Syncytial Virus (RSV) or Parainfluenza Virus&#xD;
             Type 3 (PIV3) in a clinical trial&#xD;
&#xD;
          -  Employees of the research center, any individuals involved with the conduct of the&#xD;
             study, or family members of such individuals&#xD;
&#xD;
          -  Any condition that, in the opinion of the investigator, might interfere with study&#xD;
             vaccine evaluation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Margarita Gomez, MD</last_name>
    <role>Study Director</role>
    <affiliation>MedImmune LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Primary Physicians Research</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75247</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2007</verification_date>
  <study_first_submitted>May 26, 2005</study_first_submitted>
  <study_first_submitted_qc>May 26, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2005</study_first_posted>
  <last_update_submitted>July 2, 2007</last_update_submitted>
  <last_update_submitted_qc>July 2, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 3, 2007</last_update_posted>
  <keyword>Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
    <mesh_term>Paramyxoviridae Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

